$MDWD

Fox David Morton purchased $25K of MDWD

Fox David Morton purchased 1,797 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-01.

Original reporting
SEC EDGAR · Fox David Morton
Published Jun 2, 2026, 11:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MDWD
Neutral
low confidence
Mentioned
$MDWD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDWDNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information (insider buying) but does not introduce new fundamentals such as earnings, trial results, regulatory actions, or material contracts.

02

Market read

Traders may treat this as a mild positive sentiment datapoint, but it is unlikely to be sufficient for a standalone trade without additional catalysts.

03

What to watch

No 10b5-1 plan is cited; however, the filing still lacks context on motivation, timing, or whether the buy is part of a broader pattern.

Relevance 6/10Novelty 3/10Timing: filed today (2026-06-02) for a trade dated 2026-06-01

Background

The article summarizes an SEC Form 4 insider transaction: director Fox David Morton purchased MDWD shares on 2026-06-01 and the filing was made on 2026-06-02.

Company-level read

Ticker impact

$MDWDNeutralLow confidence
Context

MediWound director Fox David Morton bought 1,797 shares in an open-market transaction, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect is typically small and fades unless followed by additional disclosures/catalysts.

Evidence & confidence

This is a routine Form 4 insider transaction with no new company-specific operational or financial information.

Market effects

No clear sector read-through; this is company-specific insider activity without disclosed new guidance/trial/contract updates.

None indicated; disclosure is US SEC filing for a single issuer.

None indicated beyond the issuer’s own investor sentiment.

Counterpoint

Insider buys under Form 4 can be discretionary or routine (e.g., liquidity/portfolio rebalancing) and may not reflect a near-term fundamental change.

Key entities

  • MediWound Ltd.

    Subject of the Form 4 insider transaction; director Fox David Morton purchased 1,797 shares at $13.9950.

  • Fox David Morton

    Director who executed the open-market purchase; holdings after transaction: 22,283 shares.

Related articles